Zacks Investment Research upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a hold rating to a buy rating in a research report released on Wednesday morning. Zacks Investment Research currently has $13.00 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
Other equities analysts have also issued research reports about the company. Maxim Group reiterated a buy rating and set a $14.00 price objective on shares of Galmed Pharmaceuticals in a research note on Thursday, November 9th. HC Wainwright reiterated a buy rating and set a $18.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, November 10th. ValuEngine lowered Galmed Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st. Roth Capital assumed coverage on Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a buy rating and a $32.00 price objective for the company. Finally, Seaport Global Securities reiterated a buy rating and set a $19.00 price objective on shares of Galmed Pharmaceuticals in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $19.20.
Galmed Pharmaceuticals (NASDAQ GLMD) traded down $0.06 during midday trading on Wednesday, hitting $11.07. The company’s stock had a trading volume of 34,068 shares, compared to its average volume of 90,738. The stock has a market cap of $140.97, a price-to-earnings ratio of -9.97 and a beta of 2.47. Galmed Pharmaceuticals has a twelve month low of $3.85 and a twelve month high of $12.22.
A hedge fund recently raised its stake in Galmed Pharmaceuticals stock. 683 Capital Management LLC lifted its holdings in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) by 9.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 549,295 shares of the biopharmaceutical company’s stock after purchasing an additional 49,295 shares during the period. 683 Capital Management LLC owned about 4.31% of Galmed Pharmaceuticals worth $5,021,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 9.85% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/14/galmed-pharmaceuticals-glmd-upgraded-to-buy-at-zacks-investment-research.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.